In Brief: OTC Monograph Feedback Wanted; China Animal Testing; More
This article was originally published in The Rose Sheet
Executive Summary
FDA continues to welcome stakeholder comment on the OTC drug monograph process, reopening the associated comment period through Aug. 1. More news in brief.